摘要
目的持续高HBV载量是慢性乙肝病情进展的主要因素。导致肝脏的炎症、坏死。应用阿德福韦酯与拉米夫定联合治疗慢性乙肝,可显著改善肝脏组织学。方法选择慢性乙肝患者且乙肝血清HBV DNA阳性患者56例,随机分为观察组和对照组,各28例。观察组给予阿德福韦酯与拉米夫定联合治疗,对照组给予阿德福韦酯治疗,观察两组治疗前及治疗后的肝功能和HBV DNA定量。结果 48周时观察组ALT恢复率(71.4%)明显高于对照组(42.9%),两组比较差异有统计学意义(P<0.05);血清HBV-DNA复制改善情况观察组(阴转率60.7%)显著优于对照组(阴转率28.6%),两组比较差异有统计学意义(P<0.05)。结论阿德福韦酯与拉米夫定联合治疗慢性乙肝HBeAg阳性可有效抑制乙肝病毒复制,明显控制病情进展和改善预后,值得临床借鉴。
【Objective】Continuous high HBV capacity is the leading actor of disease progress of chronic hepatitis B, which leads to inflammation and necrosis of liver. Applying adefovir dipivoxil and lamivudine jointly to treat chronic hepatitis B can significantly promote liver histology. 【Methods】56 cases of chronic hepatitis B HBV DNA positive are selected and divided into observation group and control group at random, 28 cases each. Cases in observation are treated by adefovir dipivoxil and lamivudine jointly; cases in control group are treated by adefovir dipivoxil. Observe the liver function of two groups before and after the treatment and quantify HBV DNA. 【Results】ALT Recovery rate（71.4%） of observation group is apparently higher than control group（42.9%） after 48 weeks. The difference has statistical meaning（P〈0.05）. The copy and improvement of HBV-DNA of observation group（negative conversion ratio 60.7%） is superior to that of control group（negative conversion ratio 28.6%）. The difference has statistical meaning（P〈0.05）. 【Conclusion】Adefovir dipivoxil and lamivudine jointly treating chronic hepatitis B HBeAg positive can effectively inhibit copy of chronic hepatitis B virus, apparently control the disease process and improve prognosis, which is worth reference.
出处
《中国医学工程》
2014年第9期18-18,20,共2页
China Medical Engineering
